Andrew Brunner

Improving the treatment of low-risk MDS: luspatercept, treatment sequencing & disease classification 02:12
Improving the treatment of low-risk MDS: luspatercept, treatment sequencing & disease classification VJHemOnc – Video Journal of Hematology & HemOnc 545 1 год назад
Treatments for MDS and Secondary AML - Part 2, High-Risk 06:13
Treatments for MDS and Secondary AML - Part 2, High-Risk AAMDSIF 168 7 месяцев назад
Expert Perspectives in Anemia in MDS - 1 on 1 with Andrew Brunner, MD 03:31
Expert Perspectives in Anemia in MDS - 1 on 1 with Andrew Brunner, MD Engage Health Media 27 1 год назад
Myelodysplastic Syndromes: Overview, Diagnosis, Therapy, and More 04:32
Myelodysplastic Syndromes: Overview, Diagnosis, Therapy, and More Blood Cancers Today 518 11 месяцев назад
Are we ready for triplet therapy in MDS? 01:37
Are we ready for triplet therapy in MDS? VJHemOnc – Video Journal of Hematology & HemOnc 87 1 год назад
Investigating the economic burden associated with treating older patients with newly diagnosed AML 02:20
Investigating the economic burden associated with treating older patients with newly diagnosed AML VJHemOnc – Video Journal of Hematology & HemOnc 54 1 год назад
The treatment protocol for higher risk MDS 03:08
The treatment protocol for higher risk MDS VJHemOnc – Video Journal of Hematology & HemOnc 1,071 3 года назад
Evolving MDS Treatment Options and the MEDALIST Trial 05:15
Evolving MDS Treatment Options and the MEDALIST Trial Blood Cancers Today 195 11 месяцев назад
The Saints & Alumni Show with Andrew Brunner '23 and Kristina Gatto '24 24:38
The Saints & Alumni Show with Andrew Brunner '23 and Kristina Gatto '24 Siena College Alumni 42 2 года назад
Andrew Brunner Real Estate Satire Video 01:11
Andrew Brunner Real Estate Satire Video Andrew Brunner 1,268 7 лет назад
The addition of lenalidomide to MEC chemotherapy to improve outcomes of patients with R/R AML 02:41
The addition of lenalidomide to MEC chemotherapy to improve outcomes of patients with R/R AML VJHemOnc – Video Journal of Hematology & HemOnc 78 1 год назад
Panel Predicts the Future for Myelodysplastic Syndromes: Treatment, Sequencing, and Research 05:53
Panel Predicts the Future for Myelodysplastic Syndromes: Treatment, Sequencing, and Research Heme Today 49 11 месяцев назад
The role of antibody-based therapies in MDS treatment 01:41
The role of antibody-based therapies in MDS treatment VJHemOnc – Video Journal of Hematology & HemOnc 98 1 год назад
Real-World Outcomes of Non-Transfusion-Dependent Patients with MDS Treated with Luspatercept 05:26
Real-World Outcomes of Non-Transfusion-Dependent Patients with MDS Treated with Luspatercept Blood Cancers Today 184 11 месяцев назад
Evaluating response criteria in myelodysplastic syndromes 03:32
Evaluating response criteria in myelodysplastic syndromes VJHemOnc – Video Journal of Hematology & HemOnc 89 2 года назад
The impact of inflammation & the microenvironment in the development and progression of MDS 01:27
The impact of inflammation & the microenvironment in the development and progression of MDS VJHemOnc – Video Journal of Hematology & HemOnc 150 1 год назад
Panel Predicts the Future for Myelodysplastic Syndromes: Treatment, Sequencing, and Research 06:01
Panel Predicts the Future for Myelodysplastic Syndromes: Treatment, Sequencing, and Research Blood Cancers Today 1,195 11 месяцев назад
Improving MDS management: new targets, drug combinations, and personalized and cellular therapies 09:25
Improving MDS management: new targets, drug combinations, and personalized and cellular therapies VJHemOnc – Video Journal of Hematology & HemOnc 360 2 года назад
An overview of the MDS diagnosis pathway 01:41
An overview of the MDS diagnosis pathway VJHemOnc – Video Journal of Hematology & HemOnc 405 3 года назад
Evaluating therapies in MDS 03:38
Evaluating therapies in MDS VJHemOnc – Video Journal of Hematology & HemOnc 39 3 года назад

Сейчас ищут